So, let's get to KG on some of these top headlines and see what is driving the price action. And let's start with crude because we of course are tracking Trump's lines this morning about a blockade of these Venezuelan oil tankers. Just talk us through the significance of that story and the impact we're seeing on the markets this morning.KJ, >> yeah, you are seeing crude up about 1.3% so far. We actually did see a pullback here a tad bit. I mean the the supply glut narrative that's taking place in the market ...

Core Insights - STERIS plc is a global leader in infection prevention and sterilization solutions with a market cap of $23.9 billion, providing a diverse range of products and services to healthcare sectors [1] Financial Performance - Analysts expect STERIS to report Q2 earnings of $2.38 per share, reflecting an 11.2% increase from $2.14 per share in the same quarter last year, with the company having consistently met or exceeded Wall Street's estimates in the past four quarters [2] - For fiscal 2026, earnings are projected to be $10.07 per share, a 9.2% increase from $9.22 in fiscal 2025 [3] Stock Performance - STERIS stock has increased by 7.9% over the past 52 weeks, underperforming the S&P 500 Index's 15.1% gain but outperforming the Health Care Select Sector SPDR Fund's 4.1% decline [4] Market Concerns - On September 25, STERIS shares fell by 3% following a national security investigation into medical equipment imports, which could result in new tariffs affecting various medical products, leading to concerns about supply chains and production costs across the healthcare manufacturing sector [5] Analyst Ratings - The consensus opinion on STERIS stock is a "Moderate Buy," with six out of nine analysts recommending a "Strong Buy" and three suggesting a "Hold," indicating a potential upside of 15% based on an average price target of $278.29 [6]

Core Insights - Fundsmith LLP, led by Terry Smith, reported a portfolio valued at $23.02 billion, with the top five holdings comprising 43.49% of total assets [1] Group 1: Top Holdings - Meta Platforms Inc. (META) is the largest holding, with 3.57 million shares valued at $2.63 billion, representing 11.44% of the portfolio, despite a reduction of 315,000 shares (-8.11%) [2] - Microsoft Corp. (MSFT) is the second-largest position, holding 4.94 million shares worth $2.46 billion, accounting for 10.68% of assets, with a modest cut of 428,653 shares (-7.98%) [3] - Stryker Corp. (SYK) holds 4.68 million shares valued at $1.85 billion, making up 8.04% of the portfolio, with a reduction of 392,000 shares (-7.74%) [4] - Philip Morris International (PM) consists of 9.07 million shares valued at $1.65 billion, representing 7.18% of the portfolio, despite trimming 1.73 million shares (-16.03%) [5] - IDEXX Laboratories (IDXX) rounds out the top five with 2.64 million shares valued at $1.42 billion, accounting for 6.15% of the portfolio, with a minor reduction of 9,042 shares (-0.34%) [6] Group 2: Investment Strategy - Fundsmith's strategy emphasizes a concentrated portfolio of high-quality companies with durable advantages, focusing on technology, healthcare, and consumer franchises [7] - The fund's approach reflects a commitment to quality growth at sensible valuations, reinforcing its reputation for consistency and long-term focus [7]

Core Viewpoint - Analysts expect Alcon to report quarterly earnings of $0.76 per share, reflecting a year-over-year decline of 2.6%, with revenues projected at $2.51 billion, an increase of 2.7% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1][2] Key Metrics Projections - Analysts estimate 'Net Sales- Total Surgical' to be $1.38 billion, representing a year-over-year increase of 2.8% [3] - The forecast for 'Net Sales- Total Vision Care' is $1.14 billion, indicating a year-over-year change of 2.7% [4] - 'Net Sales- Total Surgical- Consumables' is projected to reach $717.01 million, reflecting a 4.5% increase from the prior year [4] - 'Net Sales- Total Surgical- Equipment/other' is expected to be $223.04 million, showing a 1.8% year-over-year change [4] - 'Net Sales- Total Vision Care- Contact lenses' is anticipated to be $693.41 million, indicating a 3.3% increase from the previous year [5] - 'Net Sales- Total Vision Care- Ocular health' is projected at $441.87 million, reflecting a year-over-year change of 1.6% [5] - 'Net Sales- Total Surgical- Implantables' is expected to reach $435.74 million, indicating a 0.6% increase from the prior year [6] - The consensus for 'Revenues- Other revenues' stands at $17.50 million, reflecting a significant year-over-year increase of 16.7% [6] - 'Net sales by region- International' is projected to be $1.39 billion, indicating a 7.4% increase from the previous year [6] Stock Performance - Alcon shares have increased by 6.8% over the past month, compared to an 11.3% increase in the Zacks S&P 500 composite, with a Zacks Rank of 3 (Hold), suggesting expected performance in line with the overall market [7]